Sims T, Peterson J, Hakim M, et al. - Researchers performed this prospective, open label trial to assess the incidence of bradycardia following sugammadex use in adults. They also investigated patient and procedure features related to bradycardia following sugammadex use, and ascertained whether treatment for the bradycardia was necessary because of clinically significant hemodynamic concerns, including hypotension or clinical compromise. This study involved 200 patients ≥ 18 years of age who were administered sugammadex. Bradycardia was noted in 13 cases, developing a median of 4 minutes following sugammadex receipt. Cardiac comorbid conditions were present in two (15%) of the patients who developed bradycardia. Treatment for bradycardia with ephedrine was received by one patient. There occurred no clinically significant blood pressure alterations. In multivariable logistic regression, there was no association between initial sugammadex dose and risk of bradycardia. Findings revealed that bradycardia incidence following sugammadex use was low and not related to significant hemodynamic alterations.